December 6, 2023 Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships Product Launch

Thermo Fisher Scientific Establishes 2030 Renewable Electricity Goal and Solar Power Purchase Agreement with ib vogt

Thermo Fisher Scientific Establishes 2030 Renewable Electricity Goal and Solar Power Purchase Agreement with ib vogt Share of 127-megawatt aggregated deal in collaboration with Eurofins Scientific will power over half of Thermo Fisher’s addressable European footprint with 100% renewable electricity by 2025 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in... Read more

December 5, 2023 Bio/Pharma/CRO

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting PIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2 Data will be shared with health authorities and presented at an upcoming medical meeting... Read more

December 5, 2023 Uncategorized

Highly Flame Resistant Cellulose Fiber Composite Resin Developed with Tomoegawa Co., Ltd. and FP Chemical Industry Co.,Ltd.In a World’s First, Components Compounded with Cellulose Fibers are being Adopted for Analytical and Measuring Instruments

Highly Flame Resistant Cellulose Fiber Composite Resin Developed with Tomoegawa Co., Ltd. and FP Chemical Industry Co.,Ltd.In a World’s First, Components Compounded with Cellulose Fibers are being Adopted for Analytical and Measuring Instruments Read more

December 4, 2023 Clinical Research/Diagn. M&A, Partnerships

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets Lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities Under the terms of... Read more

December 1, 2023 Lab Top-10 PAI Top-10

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink

Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on December 14, 2023 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously... Read more

November 28, 2023 Environ, Ag./Food & Bev Lab Top-10 Licensing, IP, and Legal M&A, Partnerships PAI Top-10 Product Launch

Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences

Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences WALTHAM, Mass. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, today announced the formation of a strategic... Read more